Advertisement
Advertisement
HUMA
Humacyte, Inc. Common Stock
1.06
USDSponsored
-0.02
-1.85%
May 08, 16:00 UTC -4
Closed
After-Market
1.04
-0.02
-1.42%
HUMA Earnings Reports
Positive Surprise Ratio
HUMA beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.05M
/-$0.11
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
+582.43%
/-54.17%
Humacyte, Inc. Common Stock earnings per share and revenue
On May 08, 2026, HUMA reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.11 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.48 million, with a --% difference.
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 2.05 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Humacyte, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Humacyte, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Humacyte, Inc. Common Stock's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Humacyte, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Humacyte, Inc. Common Stock's next earnings report?
Based on 6
analysts, Humacyte, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $2.05M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement